Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREDIX HER2 neoadjuvant response-guided treatment of HER2-positive breast cancer
2014-000808-10Phase 2Active
- Sponsor
- Karolinska University Hospital
- Start
- Aug 2014
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of trastuzumab emtansine in breast cancer, sponsored by Karolinska University Hospital. Primary endpoint: Pathological objective response to primary medical treatment. Started Aug 2014; status: active.
02
Drugs
trastuzumab emtansine
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2014-000808-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000808-10.